Longevity Tech Fund

The firm focuses exclusively on early-stage companies developing technologies to extend healthy human lifespan. This spans AI-driven drug discovery, senolytic therapies, biological age diagnostics, and platforms targeting the biology of aging. It is among a small cohort of specialist venture funds in the longevity sector.

The firm invests at the Seed and Start-up stages, writing direct checks into early equity rounds. It does not participate in later growth equity or public-market positions, concentrating its risk appetite on the earliest phase of scientific and commercial validation.

Longevity Tech Fund makes direct investments in portfolio companies. It is not structured as a fund-of-funds and does not publicly allocate to external venture capital partnerships as its primary strategy.

Its mandate is narrower: the firm invests only in ventures targeting human longevity. A generalist healthtech fund might also pursue health IT, medical devices, or care delivery models. Longevity Tech Fund concentrates capital and diligence solely on the biology and technology of lifespan extension.

The firm's primary focus is North America, though publicly available information indicates it also reviews opportunities in European and Israeli longevity research hubs. It operates from a single headquarters in Boca Raton, Florida.